Importantly, we also observed a higher disproportional reporting rate associated with alpelisib compared to palbociclib, suggesting that PI3K inhibition may more directly contribute to stomatitis pathophysiology than CDK4/6 inhibition. This evidence concerns the gene CDK4 and stomatitis.